Insulet vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Insulet (PODD) and Abbott Laboratories (ABT) compare, as of Aug 14, 2026.
As of Aug 14, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Insulet trades at $146 versus a fair value of $78.48 (-46%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).
Insulet
PODD · USD · Health Care
-46%
upside to fair value
overvalued
Price$146
Fair Value$78.48
Quality71/100
Abbott Laboratories
ABT · USD · Health Care
-33%
upside to fair value
overvalued
Price$111
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
InsuletAbbott Laboratories
Valuation
37.9×P/E (TTM)27.7×
3.80×P/S (TTM)3.89×
7.27×P/B3.36×
18.7×EV/EBITDA15.1×
1.43×PEG1.47×
Profitability
10%Net margin14%
16%Operating margin13%
23%Return on equity12%
10%Return on assets6%
Growth
34%Revenue growth (YoY)8%
27.5%Avg. growth/yr (3Y)0.5%
24.5%Avg. growth/yr (5Y)5.1%
Balance & size
0.61×Debt / equity0.19×
$11BMarket cap$175B
healthyGrowth qualityhealthy
Insulet leads: 8 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Insuletof which business quality 69 · market factors 20Abbott Laboratoriesof which business quality 66 · market factors 53
ProfitabilityMargins and returns on capital today
64
50
Quality GrowthAre margins and returns improving?
66
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
37
65
Low VolatilityCalm price path (market factor)
43
83
MomentumPrice trend over the last 3–12 months (market factor)
16
43
52W MomentumDistance to the 52-week high (market factor)
2
38
Net IssuanceBuybacks instead of dilution
87
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Insulet
DCF Models$151
Earnings-Based$125
Dividend Discount$2.69
Multiples$82.16
Asset-Based$14.66
Growth DCF$158
Economic Profit$75.14
Growth Earnings$166
18 of 26 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Insulet
Bear $58.86Fair Value $78.48Bull $125
$146 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$111 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Insulet · Health Care
Quality score71 · Top 25%
Fair value upside-46% · below median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-33% · below median
Bottom line
As of Aug 14, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Insulet trades at $146 versus a fair value of $78.48 (-46%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
